Medical Oncology Clinical Trial
Official title:
A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies
NCT number | NCT05356182 |
Other study ID # | STUDY00005755 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 4, 2022 |
Est. completion date | April 2024 |
Verified date | March 2024 |
Source | State University of New York at Buffalo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main idea of this study is that a low protein diet may alter the environment surrounding the tumor, enhancing the body's immune response leading to greater anticancer effects of treatment. This study intends to use a low-protein diet as a tool to enhance the immune response generated by immune check point inhibitor treatments.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | April 2024 |
Est. primary completion date | April 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically documented solid tumor malignancies which is amenable for immunotherapy treatment with immune checkpoint inhibitors (i.e. PD1, PD-L1, CTLA inhibitors) as single agents or in combination. - Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan of the chest, abdomen, and pelvis - Life expectancy of at least 6 months - Adults = 18 years of age - Adequate hematologic, renal, and liver function as evidenced by the following: - White blood cell (WBC) = 2,500 cells/µL - Absolute neutrophil count (ANC) = 1,000 cells/µL - Platelet Count = 100,000 cells/µL - Hemoglobin (HgB) = 9.0 g/dL - Creatinine = 2.0 mg/dL - Total bilirubin = 2 x upper limit of normal (ULN) - Aspartate aminotransaminase (AST, SGOT) = 2.5 x ULN - Alanine aminotransaminase (ALT, SGPT) = 2.5 x ULN Exclusion Criteria: - • Eastern Cooperative Oncology Group (ECOG) performance status 2 or higher - Treatment with any of the following medications or interventions within 28 days of registration: - Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable. - High dose calcitriol [1,25(OH)2VitD] (i.e., > 7.0 µg/week) - A requirement for systemic immunosuppressive therapy for any reason - Any infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5°F or 38.1°C) within 1 week prior to registration - A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imaging - Any medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives |
Country | Name | City | State |
---|---|---|---|
United States | University at Buffalo / Great Lakes Cancer Care | Buffalo | New York |
Lead Sponsor | Collaborator |
---|---|
State University of New York at Buffalo |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the feasibility of low-protein diet intervention in cancer patients receiving immunotherapies. | Change in blood urea nitrogen (BUN) from baseline to post-intervention (following 3 cycles of treatment) will be measured to assess adherence of following the diet intervention. | 4 Months | |
Primary | To assess the feasibility of low-protein diet intervention in cancer patients receiving immunotherapies. | Change in urine urea nitrogen (UUN) from baseline to post-intervention (following 3 cycles of treatment) will be measured to assess adherence of following the diet intervention. | 4 Months | |
Secondary | To assess whether low-protein diet intervention augments the immune response to immunotherapies in cancer patients receiving immunotherapies | Includes isolation and characterization of antigen specific T cell clones | 4 Months | |
Secondary | To assess whether low-protein diet intervention augments the immune response to immunotherapies in cancer patients receiving immunotherapies | Includes evaluation of antigen specific T cell populations by spectratyping T cell receptor expression | 4 Months | |
Secondary | To assess whether low-protein diet intervention augments the immune response to immunotherapies in cancer patients receiving immunotherapies | Includes characterization of antigen response by cytokine and chemokine production | 4 Months | |
Secondary | To assess the enrollment rate (safety and tolerability) of the combination of immunotherapies and low-protein diet intervention | Enrollment rate | 4 Months | |
Secondary | To assess the Drop-out rate (safety and tolerability) of the combination of immunotherapies and low-protein diet intervention | Drop-out rate | 4 Months | |
Secondary | To assess the safety and tolerability of the combination of immunotherapies and low-protein diet intervention | Compliance with diet measured by self-report of patient | 4 Months | |
Secondary | To obtain preliminary evidence of clinical efficacy of immunotherapies and low-protein diet compared to immunotherapies and control-diet using the RECIST v1.1 criteria | Objective Response Rate (ORR) | 4 Months | |
Secondary | To obtain preliminary evidence of clinical efficacy of immunotherapies and low-protein diet compared to immunotherapies and control-diet using the RECIST v1.1 criteria | Progression-Free Survival (PFS) | 4 Months | |
Secondary | To obtain preliminary evidence of clinical efficacy of immunotherapies and low-protein diet compared to immunotherapies and control-diet using the RECIST v1.1 criteria | Overall Survival(OS) | 4 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02824042 -
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
|
Phase 1 | |
Completed |
NCT02253420 -
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
|
Phase 1 | |
Completed |
NCT02357953 -
Transpulmonary Thermodilution Using an Implented Central Venous Access Port
|
N/A | |
Completed |
NCT02645357 -
Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients
|
N/A | |
Recruiting |
NCT04931329 -
Onco-haematology Vigilance Card
|
||
Terminated |
NCT02138812 -
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
|
Phase 1 | |
Terminated |
NCT02368951 -
Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
|
Phase 1 | |
Not yet recruiting |
NCT05423808 -
Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients.
|
N/A | |
Terminated |
NCT02439346 -
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
|
Phase 1 | |
Recruiting |
NCT05385718 -
Ezra Faster Scan Study
|
||
Completed |
NCT02457351 -
Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
|
Phase 1 | |
Completed |
NCT02906423 -
Results From a Health System-wide Implementation of a Quality of Life Questionnaire
|
N/A | |
Completed |
NCT01409135 -
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
|
Phase 1 | |
Not yet recruiting |
NCT02327806 -
The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance
|
N/A | |
Completed |
NCT02639091 -
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
|
Phase 1 | |
Completed |
NCT02366949 -
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
|
Phase 1 | |
Not yet recruiting |
NCT06097533 -
Improvement of Quality of Life by Cannabinoids in Oncologic Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02427490 -
A Problem-Solving Intervention for Family Caregivers in Palliative Oncology
|
N/A | |
Recruiting |
NCT05359848 -
A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy
|
N/A |